List of works - Paul Whi Parren

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

scientific article

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

scientific article published on 6 January 2016

A bispecific antibody antagonizes pro-survival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies

scientific article published on 11 November 2020

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity

scientific article published in October 2007

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

scientific article

A novel label-free cell-based assay technology using biolayer interferometry

scientific article published on 28 August 2016

A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab

scientific article published on 24 November 2012

A structure-based approach to a synthetic vaccine for HIV-1.

scientific article

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

scientific article published on 17 August 2016

Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia

scientific article

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors

scientific article published on 26 December 2013

An integrated science-based approach to drug development

article

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

scientific article published on 14 September 2007

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

scientific article

Antibody C Region Influences TGN1412-like Functional Activity In Vitro

scientific article published on 12 November 2012

Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.

scientific article published on 30 September 2015

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

scientific article published on 24 August 2016

Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA.

scientific article published on 19 September 2013

Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.

scientific article published on January 2014

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA

scientific article published on 3 March 2014

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

scientific article

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities

scientific article

B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis.

scientific article published in November 2011

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

scientific article

Bispecific antibodies: a mechanistic review of the pipeline

scientific article published on 01 August 2019

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

scientific article

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

scientific article

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

scientific article published on 14 July 2017

Celebrating Antibody Therapeutics.

scientific article published in September 2017

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more

scientific article published on 16 June 2017

Characterization of a fully human IgG1 reconstructed from an anti-AChR Fab.

scientific article published on September 2003

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

scientific article published on June 2004

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

scientific article

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

scientific article published on 01 November 2008

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics

scientific article

Complement is activated by IgG hexamers assembled at the cell surface

scientific article

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

scientific article published on 01 July 2008

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

scientific article published on 4 August 2011

Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility

scientific article published on 01 May 2002

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

scientific article published on 25 September 2014

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

scientific article published on 15 January 2018

Crosstalk between human IgG isotypes and murine effector cells

scientific article published on 5 September 2012

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

scientific article

Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1

article

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.

scientific article published on 18 September 2017

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

scientific article

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

scientific article published on 15 December 2014

Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.

scientific article

Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation.

scientific article published on September 1994

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

scientific article published on 01 January 2021

Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent anti-tumor activity through DR5 agonism

scientific article published on 26 August 2020

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

scholarly article by Janine Schuurman & Paul Whi Parren published June 2016 in Current Opinion in Immunology

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

article

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

scientific article

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models

scientific article

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.

scientific article published on 24 August 2016

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

scientific article published on 11 March 2013

Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry

scientific article published on 6 April 2017

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

scientific article published on 05 June 2015

Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.

scientific article

Erratum to “Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design” [Immunol. Lett. 57 (1997) 105–112] ⬇️

scientific article published on July 1, 1997

Evidence for the involvement of the 16kD gene promoter in initiation of chromosomal replication of Escherichia coli strains carrying a B/r-derived replication origin

scientific article

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

scientific article

Fab-arm exchange: what's in a name?

scientific article published on 6 September 2012

Fc receptor but not complement binding is important in antibody protection against HIV.

scientific article published in September 2007

Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer

scientific article

Fighting the Ebola virus

scientific article published in November 2000

Functional characterization of a novel anti-B7 monoclonal antibody

article

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

scientific article published on 18 October 2011

Genetic Vaccination: One-Shot Shopping for Immediate and Sustained Protection

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

scientific article published on 03 January 2014

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

scientific article

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

scientific article

High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.

scientific article

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates

scientific article

High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.

scientific article published on 30 October 2015

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys

scientific article

Hitting Ebola, to the power of two.

scientific article published on October 2016

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

scientific article

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation

scientific article

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

scientific article published on 30 November 2009

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

scientific article published on 30 June 2011

Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice

scientific article

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

scientific article

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

scientific article

IgA EGFR antibodies mediate tumour killing in vivo

scientific article published on August 2013

Immunogenicity screening in protein drug development

scientific article published in March 2007

Immunology. Two-in-one designer antibodies

scientific article published in March 2009

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

scientific article published on 7 February 2018

In situ depletion of CD4+ T cells in human skin by Zanolimumab

scientific article published on 08 November 2006

In vitro characterization of five humanized OKT3 effector function variant antibodies.

scientific article

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

scientific article published on 30 March 2010

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap

scientific article published on 28 August 2013

Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies.

scientific article published on November 1991

Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

scientific article

Late B Cell Depletion with a Human Anti-Human CD20 IgG1 Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets

article

Listening for viral infection

scholarly article by Erica Ollmann Saphire & Paul Whi Parren published September 2001 in Nature Biotechnology

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

scientific article

Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity

scientific article

Mind the gap

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen

scientific article published on 15 June 2016

Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

scientific article

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

scientific article published on 6 January 2017

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

scientific article

Mouse/Human Chimeric IgE Antibodies Directed to the House Dust Mite Allergen Der p 2

scientific article published on 01 May 1995

N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG.

scientific article

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

scientific article

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

scientific article

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

scientific article published on June 2016

Neutralizing human Fab fragments against measles virus recovered by phage display

scientific article

Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

scientific article published on August 2002

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression

scientific article published in March 2012

Online nanoliquid chromatography–mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis

article

Opening the door to innovation

scientific article

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

scientific article published in December 1997

Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects

scientific article published on August 1, 1992

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

scientific article published on June 2002

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

scientific article published on 8 February 2016

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

scientific article

Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE

article

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

scientific article published on 22 August 2013

Quantitative Analysis of the Interaction Strength and Dynamics of Human IgG4 Half Molecules by Native Mass Spectrometry

article

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

scientific article

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

scientific article

Recognition properties of a sequence-specific DNA binding antibody

scientific article published in April 1998

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma ⬇️

scientific article published on May 31, 2012

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design ⬇️

scientific article published on June 1, 1997

Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model

scientific article published on November 2003

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

scientific article published in April 2018

Retraction for Lammerts van Bueren et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

scientific article published on 19 March 2012

Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer

article

Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength

article

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

scientific article

Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement

scientific article

Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion Da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector

scientific article published on 27 May 2015

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

scientific article published on September 2005

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

scientific article published on 16 September 2016

The INNs and outs of antibody nonproprietary names

scientific article published in January 2016

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking

scientific article published on 17 June 2016

The antiviral activity of antibodies in vitro and in vivo.

scientific article

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

scientific article published on 31 August 2011

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

scientific article published on 4 June 2012

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

scientific article published on 28 October 2011

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

scientific article

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

scientific article published on 25 November 2010

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

scientific article published on 2 November 2016

Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?

scientific article published on February 2000

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

scientific article published on 18 May 2015

gp120: Biologic aspects of structural features

scientific article published in January 2001

List of works by Paul Whi Parren

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

A bispecific antibody antagonizes pro-survival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

A novel label-free cell-based assay technology using biolayer interferometry

A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab

A structure-based approach to a synthetic vaccine for HIV-1.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors

An integrated science-based approach to drug development

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Antibody C Region Influences TGN1412-like Functional Activity In Vitro

Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA.

Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities

B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Bispecific antibodies: a mechanistic review of the pipeline

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Celebrating Antibody Therapeutics.

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more

Characterization of a fully human IgG1 reconstructed from an anti-AChR Fab.

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics

Complement is activated by IgG hexamers assembled at the cell surface

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Crosstalk between human IgG isotypes and murine effector cells

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.

Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation.

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Dual epitope targeting and enhanced hexamerization by DR5 antibodies as a novel approach to induce potent anti-tumor activity through DR5 agonism

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.

Erratum to “Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design” [Immunol. Lett. 57 (1997) 105–112] ⬇️

Evidence for the involvement of the 16kD gene promoter in initiation of chromosomal replication of Escherichia coli strains carrying a B/r-derived replication origin

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

Fab-arm exchange: what's in a name?

Fc receptor but not complement binding is important in antibody protection against HIV.

Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer

Fighting the Ebola virus

Functional characterization of a novel anti-B7 monoclonal antibody

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

Genetic Vaccination: One-Shot Shopping for Immediate and Sustained Protection

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates

High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys

Hitting Ebola, to the power of two.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.